O3‐04–07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks
The DOI matches its Crossref record.
Abstract
Neurofibrillary degeneration is correlated with clinical dementia. Methylthioninium chloride (MTC, rember) dissolves Tau polymers (Paired Helical Filaments) isolated from AD brain, and prevents Tau aggregation in cell models at the nanomolar range (0.15 – 0.58 μM). MTC has efficacy in Tau transgenic animal models, reversing cognitive and other behavioural defects, and reversing Tau pathology in the brain. An exploratory, dose-range finding, parallel design, double-blind, randomised, placebo-controlled trial of rember monotherapy was conducted in 332 subjects meeting DSM-IV and NINCDS-ADRDA for probable AD in UK and Singapore. The primary objective was to investigate the effects of oral MTC at 30, 60 and 100 mg three times per day, compared with placebo, on cognitive function (ADAS-cog) in patients with mild or moderate AD stratified by CDR. The 100mg dose was found to have a formulation defect limiting release of the therapeutic form of MTC. Secondary outcomes included MMSE, CDRsb, CGIC, ADFACS and NPI. Nested studies of SPECT- and PET-scan outcomes at 6 months are reported separately. In the prespecified analysis at 24 weeks, rember produced a significant improvement relative to placebo of -5.4 ADAS-cog units in CDR-moderate subjects at the 60mg dose. There was no placebo decline in CDR-mild AD over the first 24 weeks preventing initial efficacy analysis, although efficacy was demonstrated in mild AD by the SPECT-scan outcomes. rember stabilised the progression of AD over 50 weeks in both mild and moderate AD. The overall effect size was -6.8 ADAS-cog units vs. decline if 7.8 units in the placebo/comparator arm, with significant efficacy demonstrated separately in mild and moderate subgroups. rember efficacy was confirmed on all secondary outcomes. The rember efficacy analysis met new EMEA guidelines for disease-modifying therapy by slope analysis and two-time-point analysis, supported by SPECT and PET evidence of efficacy in brain regions strongly affected by Tau pathology. This represents the first evidence that TAI monotherapy with rember is a viable disease-modifying treatment for mild and moderate AD which may also have preventative application at preclinical Braak stages of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tau in Alzheimer Disease and Related Tauopathies
Iqbal, K., Liu, F., Gong, C.-X., & Grundke-Iqbal, I. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611592 · Cited by 1,127
Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,064
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Metadata
- Authors
- Wischik, C. M., Bentham, P., Wischik, D. J., & Seng, K. M.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2008-07
- Volume
- 4
- Issue
- 4S_Part_5
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2137228730
- Cited by
- 118
- References
- 0
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: O3‐04–07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. https://app.cochat.ai/papers/10.1016/j.jalz.2008.05.438
- The paper
- Wischik, C. M., Bentham, P., Wischik, D. J., & Seng, K. M. (2008). O3‐04–07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2008.05.438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.